source
- FDA approves Arvinas' PROTAC drug Veppanu for specific metastatic breast cancerU.S. regulators have granted approval for Veppanu, a protein-degrading therapy developed by biotech firm Arvinas, to treat a defined group of patients with metastatic, estrogen-receptor-positive, H…
- Summit Therapeutics' ivonescimab misses interim goal, shares tumble 27% as trial setback raises doubtsSummit Therapeutics reported that its experimental immunotherapy ivonescimab failed to achieve statistical significance at an interim analysis of the late-stage HARMONi-3 trial in frontline non‑sma…